Evidence map›Paper›PMID 37582740›Full record

ArticleBMC musculoskeletal disorders2023

The impact of moderate to severe osteoarthritis on the physical performance and quality of life: a cross-sectional study in Greek patients (PONOS study).

P Savvari, I Skiadas, S A Papadakis, V Psychogios, O D Argyropoulou, A P Pastroudis, G A Skarpas, A Tsoutsanis, A Garofalakis, G Katsifis and 2 more

Abstract read
In one paragraph

Article in BMC musculoskeletal disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

P SavvariInternal Medicine Department Pfizer Hellas, Neo Psychiko, 243 Mesogeion Avenue, Athens, SA, 15451, Greece. Paraskevi.Savvari@pfizer.com.
I SkiadasInternal Medicine Department Pfizer Hellas, Neo Psychiko, 243 Mesogeion Avenue, Athens, SA, 15451, Greece.
S A Papadakis2nd Orthopedic Department, KAT General Hospital of Attica, Athens, Greece.
V Psychogios5th Orthopedic Department, Asclepeion General Hospital, Athens, Greece.
O D ArgyropoulouDepartment of Pathophysiology, National and Kapodistrian University of Athens, Athens, Greece.
A P Pastroudis6th Orthopedic Department, Asclepeion General Hospital, Athens, Greece.
G A Skarpas3rd Orthopedic Department for Sports Injuries and Regenerative Medicine, Mitera General Hospital, Athens, Greece.
A Tsoutsanis6th Orthopedic Department Hygeia Hospital, Athens, Greece.
A Garofalakis1st Orthopedic Department, Mitera General Hospital, Athens, Greece.
G KatsifisRheumatology Department, Naval Hospital Athens, Athens, Greece.
D Boumpas4th Internal Medicine Department, Attikon University Hospital, Athens, Greece.
D MenegasInternal Medicine Department Pfizer Hellas, Neo Psychiko, 243 Mesogeion Avenue, Athens, SA, 15451, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundOsteoarthritis (OA) represents a leading cause of disability with limited data available for the Greek patients.

objectivesTo evaluate the impact of moderate to severe symptomatic hip/knee OA under treatment on physical performance and quality of life.

methodsA non-interventional, cross-sectional, epidemiological study of patients with moderate/severe OA, recruited in a single visit from 9 expert sites in Athens, Greece. Assessments were based on commonly used outcome scales: the Hip disability and Osteoarthritis Outcome Score (HOOS), the Knee Injury and Osteoarthritis Outcome Score (KOOS) and the EuroQol-5-Dimensions 3-levels questionnaire (EQ-5D-3L).

resultsOne hundred sixty-four patients were included in the analysis. Most of the patients were females (78.7%), with a mean age of 70.5 ± 10.2 years. Comorbidities were reported by 87.2% of patients with hypertension being the most frequently reported (53.7%), followed by dyslipidemia (31.1%), obesity (24.4%) and diabetes mellitus (23.2%). Paracetamol was the most common treatment (96%), followed by NSAIDs (75%), opioids (50%) and locally applied medications (42.7%). Both hip and knee OA patients showed substantial deterioration in health-related quality of life (QoL) and health status as reflected by the HOOS/KOOS (Function in sport and recreation was the most impaired subscale, followed by Hip- or Knee-related QoL). The mean EQ-5D-3L index score was 0.396 ± 0.319 and the mean EQ-VAS score was 52.1 ± 1.9. When compared indirectly to the local population norms our OA population had worse QoL indices.

conclusionOur findings suggest the functional disability and impaired QoL of Greek patients with moderate/severe hip/knee OA under treatment emphasizing the need for novel treatments that will reduce the burden of the disease.

Indexed as

Osteoarthritis, HipOsteoarthritis, KneeAgedAged, 80 and overCross-Sectional StudiesFemaleGreeceHumansMaleMiddle AgedPhysical Functional PerformanceQuality of LifeHealth Related Quality of Life (HRQoL)Hip osteoarthritisJoint diseasesKnee osteoarthritisMusculoskeletal diseases

Identifiers

PMID37582740
PMCPMC10426090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.